joejax

China Biotech Smallcaps: Are They for Real?

Biostar is an American company that owns the Chinese pharmaceuticals co. It went public in the U.S. after going through an exhausting registration process with the SEC. I'm an investor in the co., who went over to see the pharmaceutical facilities and meet with the CEO and other top execs three years ago. Only then did I invest. At the time of our meeting, the CEO laid out an ambitious marketing plan to increase revenue and geographic customer reach in China (it does not export), particularly its drug approved by the Chinese government for over-the-counter sale to cure Hepatits B, which is said to afflict some 10% of Chinese. My recollection is that the co. was then bringing in some $5 million in annual revenue. As was pointed out by Mr. Furman, the co. brought in $33 million in revenue in the last fiscal year. Earnings have grown handsomely as well. The co.'s financial statements are rigorously examined by its Chinese-American CFO (with doctorate in accounting from a U.S. educational institution), whom I have met on several occasions. To answer Mr. Furman's question: Biostar is definitely for real.
Joseph Amiel

HP's Acquisition of EDS Misses Real Market Opportunity

It might have been helpful if Mr. Kaplan had paid attention to where H-P is going, not where it's been. He might have profited from reading Dana Gardner's article in today's lineup: "HP Joins Desktone's Partner Program to Advance Virtualized Desktops as a Service." H-P's extensive R&D is wide and deep and likewise pointed toward future possibiltities, not merely innovations on the past.